| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 26 | 2015 | 2903 | 1.450 |
Why?
|
| Neoplasms | 21 | 2023 | 2898 | 1.330 |
Why?
|
| Neoplasm Metastasis | 19 | 2016 | 1056 | 1.130 |
Why?
|
| Prostatic Neoplasms | 9 | 2007 | 1721 | 0.710 |
Why?
|
| Radiotherapy | 6 | 2014 | 328 | 0.710 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 479 | 0.690 |
Why?
|
| Antineoplastic Agents | 8 | 2015 | 2360 | 0.510 |
Why?
|
| Knowledge | 1 | 2014 | 29 | 0.500 |
Why?
|
| Education, Medical | 2 | 2014 | 233 | 0.480 |
Why?
|
| Neovascularization, Pathologic | 6 | 2004 | 353 | 0.480 |
Why?
|
| Models, Theoretical | 3 | 2005 | 482 | 0.450 |
Why?
|
| Physicians, Primary Care | 1 | 2014 | 104 | 0.440 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2004 | 865 | 0.430 |
Why?
|
| Humans | 72 | 2023 | 86643 | 0.420 |
Why?
|
| Lymphatic Metastasis | 8 | 2003 | 486 | 0.420 |
Why?
|
| Physician-Patient Relations | 4 | 2007 | 610 | 0.400 |
Why?
|
| Radiation, Ionizing | 4 | 2010 | 121 | 0.390 |
Why?
|
| Radiation Oncology | 3 | 1997 | 119 | 0.370 |
Why?
|
| Human Experimentation | 1 | 2010 | 39 | 0.360 |
Why?
|
| Nucleoside-Diphosphate Kinase | 2 | 2000 | 11 | 0.350 |
Why?
|
| Ethics, Research | 1 | 2010 | 52 | 0.350 |
Why?
|
| Monomeric GTP-Binding Proteins | 2 | 2000 | 18 | 0.350 |
Why?
|
| Disease-Free Survival | 12 | 2011 | 1204 | 0.340 |
Why?
|
| Patient Advocacy | 3 | 2015 | 49 | 0.330 |
Why?
|
| MicroRNAs | 4 | 2015 | 534 | 0.330 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2005 | 468 | 0.320 |
Why?
|
| Genetic Therapy | 9 | 2008 | 342 | 0.310 |
Why?
|
| Physician's Role | 4 | 2005 | 179 | 0.310 |
Why?
|
| Models, Economic | 1 | 2007 | 60 | 0.300 |
Why?
|
| Hematopoiesis | 1 | 2008 | 163 | 0.300 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2005 | 1313 | 0.290 |
Why?
|
| Neoplastic Stem Cells | 1 | 2008 | 143 | 0.280 |
Why?
|
| Liver Neoplasms | 3 | 2018 | 736 | 0.280 |
Why?
|
| Decision Making | 3 | 2007 | 642 | 0.280 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2008 | 683 | 0.280 |
Why?
|
| Prostatectomy | 3 | 2007 | 471 | 0.270 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2008 | 292 | 0.270 |
Why?
|
| Androgen Antagonists | 2 | 2005 | 144 | 0.270 |
Why?
|
| Prognosis | 11 | 2005 | 3679 | 0.270 |
Why?
|
| Attitude of Health Personnel | 2 | 2005 | 636 | 0.270 |
Why?
|
| Transcription Factors | 6 | 2004 | 1565 | 0.270 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2003 | 150 | 0.260 |
Why?
|
| Colorectal Neoplasms | 3 | 2018 | 938 | 0.250 |
Why?
|
| Prostate-Specific Antigen | 2 | 1998 | 353 | 0.250 |
Why?
|
| Ethics, Medical | 3 | 2000 | 306 | 0.250 |
Why?
|
| Attitude to Health | 1 | 2005 | 220 | 0.240 |
Why?
|
| Nitriles | 1 | 2004 | 149 | 0.230 |
Why?
|
| Triazoles | 1 | 2004 | 96 | 0.230 |
Why?
|
| Biomedical Research | 3 | 2014 | 376 | 0.230 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2023 | 70 | 0.230 |
Why?
|
| History, 20th Century | 3 | 2010 | 312 | 0.220 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2003 | 68 | 0.220 |
Why?
|
| Managed Care Programs | 2 | 2000 | 42 | 0.210 |
Why?
|
| Brachytherapy | 1 | 2003 | 119 | 0.210 |
Why?
|
| Melanoma | 2 | 2013 | 459 | 0.200 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2000 | 66 | 0.200 |
Why?
|
| Disease Progression | 8 | 2012 | 1531 | 0.200 |
Why?
|
| Lymph Nodes | 4 | 2000 | 533 | 0.200 |
Why?
|
| Lymph Node Excision | 1 | 2003 | 217 | 0.200 |
Why?
|
| Aged | 16 | 2018 | 18415 | 0.200 |
Why?
|
| Biomarkers, Tumor | 3 | 2003 | 1464 | 0.200 |
Why?
|
| Medical Oncology | 2 | 2014 | 359 | 0.190 |
Why?
|
| Female | 31 | 2018 | 44532 | 0.190 |
Why?
|
| Carcinoma | 1 | 2003 | 436 | 0.180 |
Why?
|
| Survival Analysis | 6 | 2013 | 1538 | 0.180 |
Why?
|
| Combined Modality Therapy | 9 | 2005 | 1686 | 0.180 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 546 | 0.170 |
Why?
|
| Clinical Trials as Topic | 4 | 2014 | 1169 | 0.170 |
Why?
|
| Cadherins | 1 | 2000 | 151 | 0.170 |
Why?
|
| Middle Aged | 16 | 2018 | 25028 | 0.170 |
Why?
|
| Radiosurgery | 2 | 2013 | 272 | 0.170 |
Why?
|
| Mammography | 2 | 2000 | 463 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2005 | 292 | 0.160 |
Why?
|
| Gene Amplification | 1 | 2018 | 131 | 0.160 |
Why?
|
| History, 21st Century | 2 | 2009 | 175 | 0.140 |
Why?
|
| Immediate-Early Proteins | 4 | 2004 | 164 | 0.140 |
Why?
|
| Mastectomy | 2 | 2004 | 243 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2000 | 380 | 0.140 |
Why?
|
| Antigens, Neoplasm | 1 | 1998 | 325 | 0.140 |
Why?
|
| Disease Models, Animal | 4 | 2016 | 2232 | 0.130 |
Why?
|
| Prescription Fees | 1 | 2015 | 10 | 0.130 |
Why?
|
| Consumer Advocacy | 1 | 1995 | 10 | 0.130 |
Why?
|
| Insurance Coverage | 1 | 1996 | 117 | 0.130 |
Why?
|
| Health Care Rationing | 1 | 1996 | 83 | 0.130 |
Why?
|
| Microcirculation | 3 | 2000 | 106 | 0.130 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 6509 | 0.130 |
Why?
|
| United States | 7 | 2015 | 6672 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2015 | 49 | 0.130 |
Why?
|
| Drug Costs | 1 | 2015 | 62 | 0.130 |
Why?
|
| Erectile Dysfunction | 2 | 2007 | 74 | 0.130 |
Why?
|
| Neoplasm Staging | 5 | 2004 | 1939 | 0.120 |
Why?
|
| Patients | 1 | 1995 | 100 | 0.120 |
Why?
|
| Medical Laboratory Science | 1 | 1994 | 7 | 0.120 |
Why?
|
| Radiotherapy, Computer-Assisted | 2 | 2008 | 25 | 0.120 |
Why?
|
| Clinical Medicine | 1 | 1994 | 34 | 0.120 |
Why?
|
| Aging | 1 | 1998 | 691 | 0.120 |
Why?
|
| Life Expectancy | 1 | 1994 | 86 | 0.120 |
Why?
|
| Genetic Engineering | 1 | 1994 | 114 | 0.110 |
Why?
|
| Patient Participation | 1 | 2015 | 216 | 0.110 |
Why?
|
| Urinary Incontinence | 2 | 2007 | 206 | 0.110 |
Why?
|
| Male | 13 | 2018 | 40965 | 0.110 |
Why?
|
| Adult | 12 | 2018 | 25648 | 0.110 |
Why?
|
| History, 19th Century | 2 | 2009 | 59 | 0.110 |
Why?
|
| Health Care Reform | 1 | 1994 | 90 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 2 | 2004 | 297 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2013 | 7993 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 469 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2005 | 429 | 0.100 |
Why?
|
| Informed Consent | 2 | 2010 | 266 | 0.100 |
Why?
|
| Animals | 15 | 2016 | 26582 | 0.100 |
Why?
|
| Neoplasm Transplantation | 6 | 2016 | 391 | 0.090 |
Why?
|
| Age Factors | 3 | 2007 | 1851 | 0.090 |
Why?
|
| Philosophy, Medical | 2 | 2005 | 17 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2000 | 3640 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 1998 | 999 | 0.090 |
Why?
|
| Ohio | 1 | 2010 | 37 | 0.090 |
Why?
|
| Tamoxifen | 2 | 2004 | 168 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 1991 | 177 | 0.090 |
Why?
|
| Biological Evolution | 1 | 1997 | 919 | 0.090 |
Why?
|
| NM23 Nucleoside Diphosphate Kinases | 2 | 2000 | 5 | 0.090 |
Why?
|
| Lung | 2 | 2012 | 1170 | 0.090 |
Why?
|
| Research Subjects | 1 | 2010 | 73 | 0.090 |
Why?
|
| X-Ray Therapy | 1 | 2008 | 6 | 0.090 |
Why?
|
| Universities | 1 | 2010 | 135 | 0.080 |
Why?
|
| Cell Line, Tumor | 5 | 2015 | 2426 | 0.080 |
Why?
|
| Lung Neoplasms | 3 | 2013 | 2262 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2004 | 912 | 0.080 |
Why?
|
| Military Personnel | 1 | 2010 | 85 | 0.080 |
Why?
|
| Survival Rate | 3 | 2012 | 1863 | 0.080 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2008 | 94 | 0.080 |
Why?
|
| Adenocarcinoma | 3 | 2012 | 1169 | 0.080 |
Why?
|
| Melanoma, Experimental | 1 | 2008 | 103 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 83 | 0.080 |
Why?
|
| Philosophy | 1 | 2007 | 9 | 0.080 |
Why?
|
| Urethral Stricture | 1 | 2007 | 13 | 0.080 |
Why?
|
| Rectal Diseases | 1 | 2007 | 24 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 1993 | 582 | 0.080 |
Why?
|
| Critical Pathways | 1 | 2007 | 35 | 0.080 |
Why?
|
| DNA-Binding Proteins | 4 | 2004 | 1208 | 0.080 |
Why?
|
| Mutation | 1 | 2018 | 3968 | 0.070 |
Why?
|
| Actuarial Analysis | 2 | 1997 | 66 | 0.070 |
Why?
|
| Time Factors | 4 | 2005 | 5210 | 0.070 |
Why?
|
| Phenotype | 3 | 2015 | 2378 | 0.070 |
Why?
|
| Fund Raising | 1 | 2005 | 2 | 0.070 |
Why?
|
| Academies and Institutes | 1 | 2006 | 31 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2003 | 1673 | 0.070 |
Why?
|
| Dermatology | 1 | 2006 | 35 | 0.070 |
Why?
|
| Gene Expression Regulation | 3 | 2002 | 1920 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2000 | 1753 | 0.070 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 1384 | 0.070 |
Why?
|
| Trastuzumab | 1 | 2005 | 68 | 0.070 |
Why?
|
| Heterografts | 2 | 2015 | 98 | 0.060 |
Why?
|
| Sample Size | 1 | 2005 | 130 | 0.060 |
Why?
|
| Mastectomy, Radical | 2 | 1995 | 10 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2003 | 916 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2007 | 455 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 114 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2007 | 814 | 0.060 |
Why?
|
| Radiation Dosage | 2 | 2011 | 227 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2004 | 295 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2004 | 2438 | 0.060 |
Why?
|
| Carcinoma, Lewis Lung | 2 | 2000 | 23 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2005 | 427 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 552 | 0.050 |
Why?
|
| Mice | 9 | 2015 | 11352 | 0.050 |
Why?
|
| Interdisciplinary Communication | 1 | 2003 | 130 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2004 | 182 | 0.050 |
Why?
|
| Early Growth Response Protein 1 | 4 | 2004 | 54 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 860 | 0.050 |
Why?
|
| Lymphedema | 1 | 2003 | 77 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 280 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 1991 | 0.050 |
Why?
|
| Coumarins | 1 | 2000 | 13 | 0.050 |
Why?
|
| Risk | 1 | 2003 | 674 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2000 | 188 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 689 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 177 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2005 | 2261 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 5 | 2002 | 1041 | 0.050 |
Why?
|
| Gene Expression | 2 | 2015 | 1284 | 0.050 |
Why?
|
| Cisplatin | 1 | 2002 | 612 | 0.050 |
Why?
|
| Databases as Topic | 1 | 2000 | 92 | 0.040 |
Why?
|
| Mice, Nude | 5 | 2002 | 790 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2005 | 930 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2001 | 156 | 0.040 |
Why?
|
| Carcinoma, Lobular | 1 | 2000 | 81 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 1376 | 0.040 |
Why?
|
| Plasminogen | 1 | 1998 | 41 | 0.040 |
Why?
|
| Apoptosis | 3 | 2008 | 1683 | 0.040 |
Why?
|
| Genetic Vectors | 4 | 2004 | 439 | 0.040 |
Why?
|
| Class II Phosphatidylinositol 3-Kinases | 1 | 2018 | 8 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2000 | 157 | 0.040 |
Why?
|
| Research | 2 | 2003 | 253 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 85 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 1135 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 1997 | 78 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 1801 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2011 | 458 | 0.040 |
Why?
|
| Mutagenesis | 1 | 1997 | 199 | 0.040 |
Why?
|
| Adrenalectomy | 1 | 1996 | 43 | 0.040 |
Why?
|
| Axilla | 1 | 1997 | 99 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 532 | 0.040 |
Why?
|
| Insurance, Health | 1 | 1998 | 160 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 1998 | 460 | 0.040 |
Why?
|
| Ovariectomy | 1 | 1996 | 81 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2016 | 151 | 0.040 |
Why?
|
| Researcher-Subject Relations | 1 | 1996 | 4 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 407 | 0.030 |
Why?
|
| Molecular Biology | 1 | 1996 | 89 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 1075 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2001 | 629 | 0.030 |
Why?
|
| Social Responsibility | 1 | 1996 | 57 | 0.030 |
Why?
|
| Fibrosarcoma | 1 | 1995 | 84 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2015 | 57 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 1996 | 176 | 0.030 |
Why?
|
| DNA Repair | 1 | 1997 | 356 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 1997 | 579 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 1995 | 89 | 0.030 |
Why?
|
| Algorithms | 1 | 2003 | 1830 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 187 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 1995 | 251 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2015 | 252 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 1996 | 859 | 0.030 |
Why?
|
| Research Design | 2 | 2003 | 594 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 289 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 1995 | 269 | 0.030 |
Why?
|
| Social Values | 1 | 1994 | 44 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 1996 | 567 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1995 | 596 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 1994 | 71 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 1995 | 384 | 0.030 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1994 | 101 | 0.030 |
Why?
|
| Health Care Costs | 1 | 1995 | 238 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 1995 | 203 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 579 | 0.030 |
Why?
|
| Forecasting | 1 | 1994 | 304 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 266 | 0.030 |
Why?
|
| Adenoviridae | 2 | 2004 | 345 | 0.030 |
Why?
|
| Social Change | 1 | 1991 | 7 | 0.030 |
Why?
|
| England | 1 | 1991 | 41 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1991 | 78 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 270 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 369 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1991 | 153 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2011 | 260 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2014 | 395 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2004 | 937 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1996 | 1076 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 20 | 0.020 |
Why?
|
| Etanercept | 1 | 2008 | 32 | 0.020 |
Why?
|
| Esophageal Neoplasms | 2 | 2002 | 321 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2008 | 43 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 88 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1993 | 508 | 0.020 |
Why?
|
| Rats | 2 | 2004 | 3990 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 1991 | 1823 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 456 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1197 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 1991 | 426 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2000 | 8489 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2008 | 428 | 0.020 |
Why?
|
| Necrosis | 2 | 1996 | 204 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 2705 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2004 | 45 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2004 | 94 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2004 | 69 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1996 | 557 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 235 | 0.010 |
Why?
|
| Genes, erbB-2 | 1 | 2003 | 24 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 977 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 355 | 0.010 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2003 | 34 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2000 | 3092 | 0.010 |
Why?
|
| Receptors, Steroid | 1 | 2003 | 42 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 460 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 393 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2004 | 712 | 0.010 |
Why?
|
| Phytotherapy | 1 | 2003 | 133 | 0.010 |
Why?
|
| Isocoumarins | 1 | 2000 | 7 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2000 | 46 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 592 | 0.010 |
Why?
|
| Laminin | 1 | 2000 | 85 | 0.010 |
Why?
|
| ROC Curve | 1 | 2003 | 752 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2000 | 224 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2000 | 121 | 0.010 |
Why?
|
| Mass Screening | 1 | 2004 | 618 | 0.010 |
Why?
|
| Collagen | 1 | 2000 | 269 | 0.010 |
Why?
|
| Angiostatins | 1 | 1998 | 15 | 0.010 |
Why?
|
| Cytokines | 1 | 2003 | 776 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2000 | 435 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 556 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 2767 | 0.010 |
Why?
|
| Cell Movement | 1 | 2000 | 758 | 0.010 |
Why?
|
| Biomarkers | 1 | 2003 | 1718 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 1961 | 0.010 |
Why?
|
| Mastadenovirus | 1 | 1995 | 4 | 0.010 |
Why?
|
| Liposomes | 1 | 1995 | 91 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2000 | 2818 | 0.010 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1995 | 109 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 1995 | 168 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1995 | 363 | 0.010 |
Why?
|
| Thrombosis | 1 | 1996 | 296 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2003 | 3241 | 0.010 |
Why?
|